PT1523329E - Partícula viral adjuvante - Google Patents

Partícula viral adjuvante Download PDF

Info

Publication number
PT1523329E
PT1523329E PT37399136T PT03739913T PT1523329E PT 1523329 E PT1523329 E PT 1523329E PT 37399136 T PT37399136 T PT 37399136T PT 03739913 T PT03739913 T PT 03739913T PT 1523329 E PT1523329 E PT 1523329E
Authority
PT
Portugal
Prior art keywords
papmv
virus
particle
protein
immune response
Prior art date
Application number
PT37399136T
Other languages
English (en)
Portuguese (pt)
Inventor
Denis Leclerc
Nathalie Majeau
Constantino Roberto Lopez-Macias Iii
Original Assignee
Folia Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Folia Biotech Inc filed Critical Folia Biotech Inc
Publication of PT1523329E publication Critical patent/PT1523329E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/26011—Flexiviridae
    • C12N2770/26023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PT37399136T 2002-07-05 2003-06-30 Partícula viral adjuvante PT1523329E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39365902P 2002-07-05 2002-07-05

Publications (1)

Publication Number Publication Date
PT1523329E true PT1523329E (pt) 2013-10-08

Family

ID=30115621

Family Applications (1)

Application Number Title Priority Date Filing Date
PT37399136T PT1523329E (pt) 2002-07-05 2003-06-30 Partícula viral adjuvante

Country Status (14)

Country Link
US (2) US7641896B2 (enExample)
EP (2) EP2272525A3 (enExample)
JP (1) JP4953570B2 (enExample)
KR (1) KR20050044886A (enExample)
CN (1) CN1665528B (enExample)
AU (1) AU2003281246A1 (enExample)
BR (1) BR0312474A (enExample)
CA (1) CA2434000C (enExample)
DK (1) DK1523329T3 (enExample)
ES (1) ES2431963T3 (enExample)
MX (1) MXPA05000287A (enExample)
NO (1) NO20050396L (enExample)
PT (1) PT1523329E (enExample)
WO (1) WO2004004761A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434000C (en) * 2002-07-05 2012-07-17 Denis Leclerc Adjuvant viral particle
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
JP2008513035A (ja) * 2004-09-21 2008-05-01 サイトス バイオテクノロジー アーゲー Ａｐ２０５のコートタンパク質と抗原性ポリペプチドとの融合タンパク質を含んでなるウイルス粒子
CN101119749A (zh) 2004-10-25 2008-02-06 赛托斯生物技术公司 肠抑胃肽(gip)抗原阵列及其用途
KR100688522B1 (ko) * 2005-01-18 2007-03-02 삼성전자주식회사 영상데이터 압축기 및 압축방법
WO2007053188A2 (en) 2005-06-01 2007-05-10 Dow Global Technologies, Inc. Production of multivalent virus like particles
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
EP2078086A4 (en) * 2006-11-15 2010-06-30 Folia Biotech Inc PAPAYAMOSAIC VIRUS-BASED IMMUNOGENE AFFINITY-CONJUGATED ANTIGENSYSTEMS AND THEIR USES
WO2012048430A1 (en) * 2010-10-14 2012-04-19 Folia Biotech Inc. Affinity-conjugated nucleoprotein-papaya mosaic virus-like particles and uses thereof
CA2669485C (en) * 2006-11-15 2017-01-03 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza
JP2010516713A (ja) * 2007-01-26 2010-05-20 フォーリア バイオテック インコーポレーテッド 腸チフス菌および他の腸内細菌病原体に対するパパイアモザイクウィルスベースのワクチン
US20090093019A1 (en) * 2007-04-27 2009-04-09 Phelps Jamie P Production and in vivo assembly of soluble recombinant icosahedral virus-like particles
JP2010538619A (ja) * 2007-09-11 2010-12-16 ユニベルシテ ラヴァル Ｍａｌｖａモザイクウイルスおよびウイルス様粒子およびこれらの使用
US20110189231A1 (en) * 2008-06-17 2011-08-04 Denis Leclerc Compositions Comprising Salmonella Porins and Uses Thereof as Adjuvants and Vaccines
WO2010012069A1 (en) * 2008-07-30 2010-02-04 Folio Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
WO2012078069A1 (en) 2010-12-09 2012-06-14 Iosif Grigorievich Atabekov Spherical nano- and microparticles derived from plant viruses for the display of foreign proteins or epitopes
AU2012255595A1 (en) 2011-05-13 2013-12-12 Folia Biotech Inc. Virus-like particles and process for preparing same
TR201905619T4 (tr) 2011-06-09 2019-05-21 Biomay Ag Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
HK1203983A1 (en) * 2012-04-02 2015-11-06 Folia Biotech Inc. Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines
JP2016531927A (ja) * 2013-09-19 2016-10-13 フォリア バイオテック インコーポレイテッド 癌治療でのパパイヤモザイクウイルス及びウイルス様粒子
WO2016176558A1 (en) * 2015-04-30 2016-11-03 The Regents Of The University Of California Adjuvant particles comprising adenosine receptor antagonists
CN115956125A (zh) * 2020-03-31 2023-04-11 医学噬菌体生物制药公司 用于产生病毒样颗粒的载体及其用途
EP4277654A1 (en) 2021-01-18 2023-11-22 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN118684781A (zh) * 2023-03-21 2024-09-24 深圳赫兹生命科学技术有限公司 GnRH-VLP重组去势疫苗及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79880A0 (en) 1985-08-29 1986-11-30 Inst Medical W & E Hall Recombinant virus
US5977438A (en) 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
CA2089497A1 (en) 1990-08-15 1992-02-16 Lendon Payne Self-assembling replication defective hybrid virus particles
US5443969A (en) * 1992-10-29 1995-08-22 Rutgers University RNA packaging system
GB9414118D0 (en) 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
CA2202761A1 (en) 1994-10-18 1996-04-25 Sean Nicholas Chapman Method of producing a chimeric protein
GB9607899D0 (en) 1996-04-17 1996-06-19 Scottish Crop Research Inst Virus-like particle
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
EP0980257A1 (en) * 1997-05-01 2000-02-23 Chiron Corporation Use of virus-like particles as adjuvants
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
DE19752855C2 (de) 1997-11-28 2003-04-03 Bundesrepublik Deutschland Let Retrovirale Pseudotyp-Vektoren mit modifizierten Oberflächen-Hüllproteinen und Verpackungszelle zu ihrer Herstellung für den selektiven Gentransfer
GB9806666D0 (en) 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
JP2002522029A (ja) 1998-07-27 2002-07-23 ジェネンテック・インコーポレーテッド コートタンパク質の改変によるファージ提示における改良した形質転換効率
FR2786773B1 (fr) 1998-12-03 2002-03-08 Univ Paris Curie Proteines d'enveloppe, methodes et utilisations
EP2351768B1 (en) 1998-12-04 2014-06-18 Biogen Idec MA Inc. HBV core antigen particles with multiple immunogenic components attached via peptide ligands
DE19904800C1 (de) 1999-02-05 2001-02-08 Eberhard Hildt Partikel zur Gentherapie
GB9921337D0 (en) * 1999-09-09 1999-11-10 Axis Genetics Plc Modified plant viruses
GB9924352D0 (en) 1999-10-14 1999-12-15 Hellendoorn Koen Methods,compositions and applications relating to the generation of novel plant viral particles
GB9924351D0 (en) * 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US6730306B1 (en) 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
AUPQ661600A0 (en) 2000-03-31 2000-05-04 Macfarlane Burnet Centre For Medical Research Limited, The A nucleic acid construct and methods related thereto
IT1317046B1 (it) * 2000-06-16 2003-05-26 Ist Superiore Sanita Proteina di fusione, particelle virali chimeriche che la espongono sulcapside, piante infettate con tali particelle, loro usi e composizioni
CA2414396A1 (en) 2000-06-26 2002-01-03 The United States Of America, As Represented By The Secretary Of Agricul Ture Production of vaccines using transgenic plants
WO2002004007A2 (en) 2000-07-06 2002-01-17 Georgetown University Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
GB0028319D0 (en) * 2000-11-20 2001-01-03 Univ Southampton Materials and methods relating to fusion proteins for inducing an immune response
ITRM20010332A1 (it) * 2001-06-11 2002-12-11 Ist Superiore Sanita Vaccini a subunita' e procedimenti per la loro produzione.
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
CA2434000C (en) * 2002-07-05 2012-07-17 Denis Leclerc Adjuvant viral particle

Also Published As

Publication number Publication date
US20090280145A1 (en) 2009-11-12
US8282940B2 (en) 2012-10-09
BR0312474A (pt) 2005-04-26
HK1075214A1 (en) 2005-12-09
NO20050396L (no) 2005-01-25
WO2004004761A3 (en) 2004-05-06
EP2272525A3 (en) 2011-11-16
CN1665528B (zh) 2013-05-15
DK1523329T3 (da) 2013-10-14
KR20050044886A (ko) 2005-05-13
CA2434000C (en) 2012-07-17
AU2003281246A1 (en) 2004-01-23
EP2272525A2 (en) 2011-01-12
WO2004004761A2 (en) 2004-01-15
EP1523329B1 (en) 2013-07-24
US20050048082A1 (en) 2005-03-03
ES2431963T3 (es) 2013-11-28
JP2006504644A (ja) 2006-02-09
CA2434000A1 (en) 2004-01-05
MXPA05000287A (es) 2005-09-08
CN1665528A (zh) 2005-09-07
US7641896B2 (en) 2010-01-05
JP4953570B2 (ja) 2012-06-13
EP1523329A2 (en) 2005-04-20

Similar Documents

Publication Publication Date Title
US8282940B2 (en) Adjuvant viral particle
ES2139879T5 (es) Adyuvante de la mucosa no toxico.
Azegami et al. Challenges in mucosal vaccines for the control of infectious diseases
TWI364294B (en) Chimeric antigens for breaking host tolerance to foreign antigens
Haller et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins
PT1233782E (pt) Estimulação da produção de anticorpos específicos para o hcv
US20140161836A1 (en) Carious tooth vaccine and preparation method
BRPI0612293A2 (pt) conjugados antigênicos e usos dos mesmos
ES2648337T3 (es) Uso del PACAP como adyuvante molecular para vacunas
AU2005279590B2 (en) Vaccine composition against hepatitis C virus
KR20070048140A (ko) 온코세르카 볼불러스의 천연 생성물의 항원보강성 및 면역강화 특성
Arnon et al. Peptide-based synthetic recombinant vaccines with anti-viral efficacy
Batdelger et al. Clinical experience with therapeutic vaccines designed for patients with hepatitis
JP5960064B2 (ja) ヒトプロガストリンペプチドに対する免疫原性組成物
Astori et al. Recombinant fusion peptides containing single or multiple repeats of a ubiquitous T-helper epitope are highly immunogenic
HK1151730A (en) Adjuvant viral particle
RU2294212C2 (ru) Вакцинный состав, потенцированный комбинацией днк и антигена
HK1075214B (en) Adjuvant viral particle
JPH06199894A (ja) Ｃ型肝炎ウイルスのコア蛋白質領域に存在するｔ細胞エピトープ
WO2004004764A1 (ja) 抗ホワイトスポット病組成物
Ramesh Introduction to Recombinant Vaccines
Melief Synthetic vaccines
CN113876941A (zh) 一种新的快速高效低价的人工合成疫苗的设计和应用
Ben-Yedidia A peptide-based vaccine against influenza
BR112019008624B1 (pt) Composição de vacina, e, uso da mesma